Radiopharm Theranostics Ltd
RADX Nasdaq Pharmaceutical Preparations Financials FY2023โFY2026
What Radiopharm Theranostics Ltd does
No business description yet.
- Legal name
- Radiopharm Theranostics Ltd
- Fiscal year ends
- June 30, 2026
- Latest annual report
- 20-F ยท Sep 30, 2026
- Accession ยท CIK
- 0001213900-26-105181
0001949257
Revenue and margins
Radiopharm Theranostics Ltd had $2.8M of revenue in fiscal 2026, down 23.8% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was โ in fiscal 2026, โ of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Radiopharm Theranostics Ltd returned โ to shareholders in fiscal 2026. The diluted share count rose 47.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably Radiopharm Theranostics Ltd can carry it.
| Fiscal year end | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Cash and short-term investments | $11.7M | $18.6M | $29.1M | $4.1M |
| Interest coverage | โ400.5x | โ73.4x | โ584.6x | โ505.2x |
| Current ratio | โ | 1.3x | 2.7x | 1.2x |
| Quick ratio | โ | 1.3x | 2.7x | 1.2x |
| Total assets | โ | $72.0M | $86.5M | $60.1M |
| Total liabilities | โ | $44.7M | $43.6M | $37.8M |
| Shareholders' equity | $45.6M | $27.4M | $42.9M | $22.3M |
| Net debt (โ = net cash) | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 5 | 4 / 8 | 3 / 8 |
| Accruals ratio | โ | โ34.7% | โ2.1% | โ5.7% |
| Altman Z'' | โ | โ | โ | โ |
4 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.3M | $0.3M | $3.6M | $2.8M |
| Gross profit | $0.3M | $0.3M | $0.0M | $0.3M |
| Research and development | $22.6M | $23.1M | $27.5M | $50.0M |
| Operating income | โ$34.5M | โ$47.2M | โ$38.2M | โ$56.8M |
| Interest expense | $0.1M | $0.6M | $0.1M | $0.1M |
| Pretax income | โ$34.6M | โ$47.9M | โ$38.2M | โ$56.9M |
| Income tax | $0.0M | $0.1M | $0.1M | $0.1M |
| Net income | โ$34.6M | โ$47.9M | โ$38.3M | โ$57.0M |
| Diluted EPS | โ$3,396.00 | โ$3,723.00 | โ$528.00 | โ$537.00 |
| Diluted shares | 0.00B | 0.00B | 0.01B | 0.01B |
| Cash flow | ||||
| Cash from operations | โ$23.2M | โ$23.0M | โ$36.6M | โ$52.8M |
| Capital expenditure | $0.0M | โ | โ | โ |
| Free cash flow | โ$23.2M | โ | โ | โ |
| Depreciation and amortization | $3.3M | $3.1M | $2.6M | $2.7M |
| Stock-based compensation | $3.0M | $2.6M | $1.9M | $2.4M |
| Balance sheet | ||||
| Cash and short-term investments | $11.7M | $18.6M | $29.1M | $4.1M |
| Current assets | โ | $22.8M | $39.9M | $21.9M |
| Current liabilities | โ | $17.6M | $14.9M | $18.9M |
| Property and equipment, net | โ | $0.1M | $0.1M | $0.0M |
| Intangible assets | $58.5M | $49.1M | $46.6M | $38.2M |
| Total assets | โ | $72.0M | $86.5M | $60.1M |
| Total liabilities | โ | $44.7M | $43.6M | $37.8M |
| Shareholders' equity | $45.6M | $27.4M | $42.9M | $22.3M |
| Margins | ||||
| Gross margin | 100.0% | 100.0% | 1.1% | 9.5% |
| Operating margin | โ11,794.5% | โ15,778.7% | โ1,050.6% | โ2,051.5% |
| EBITDA margin | โ10,667.1% | โ14,733.8% | โ979.2% | โ1,953.7% |
| Net margin | โ11,836.9% | โ16,025.8% | โ1,055.3% | โ2,057.5% |
| FCF margin | โ7,950.4% | โ | โ | โ |
| Returns | ||||
| Return on capital employed | โ | โ86.7% | โ53.4% | โ137.7% |
| Return on equity | โ75.9% | โ131.5% | โ109.2% | โ174.7% |
| Return on assets | โ | โ66.6% | โ48.4% | โ77.7% |
| Growth | ||||
| Revenue growth | โ | 2.3% | 1,114.4% | โ23.8% |
| Share count change | โ | 26.4% | 438.5% | 47.7% |
| Financial health | ||||
| Interest coverage | โ400.5x | โ73.4x | โ584.6x | โ505.2x |
| Current ratio | โ | 1.3x | 2.7x | 1.2x |
| Quick ratio | โ | 1.3x | 2.7x | 1.2x |
| Capital allocation | ||||
| Capex / revenue | 15.5% | โ | โ | โ |
| Stock comp / revenue | 1,039.0% | 882.4% | 52.2% | 86.9% |
| Quality scores | ||||
| Piotroski F-score | โ | โ | 4.0 | 3.0 |
| Accruals ratio | โ | โ34.7% | โ2.1% | โ5.7% |
Source: SEC EDGAR XBRL filings (CIK 0001949257). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Per-share figures are per US-listed share (1 ADS = 300 ordinary shares). For information only โ not investment advice. Check the original filings before relying on any figure.